<DOC>
	<DOC>NCT02925494</DOC>
	<brief_summary>This is an extension study for women who have already received six months of treatment in the phase III clinical trial M12-815 or M12-817, and will evaluate the long-term efficacy and safety of elagolix administered alone and in combination with estradiol/norethindrone acetate for an additional six months in the treatment of heavy menstrual bleeding associated with uterine fibroids.</brief_summary>
	<brief_title>An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Participant has completed the 6Month Treatment Period of their respective Pivotal Study (either Study M12815 or Study M12817). Participant did not meet removal criteria in bone mineral density (BMD) decrease in the spine, total hip and femoral neck at Month 6 of the Treatment Period of their respective Pivotal Study Participant has negative urine and/or serum pregnancy test(s) results were consistently negative during the Treatment Period of their respective Pivotal Study and prior to first dose in this study. Participant's endometrial biopsy from the Month 6 Visit of their respective Pivotal Study shows no clinically significant endometrial pathology. Participant met criteria for removal from therapy in her respective Pivotal Study. Participant is planning a pregnancy within the next 18 months. Participant has current suicidal markers as noted at the Month 6 visit of her respective pivotal study. Participant has any new medical conditions that may be unsuitable for participation. Participant is using any systemic corticosteroids for over 14 days or is likely to require treatment with systemic corticosteroids during the course of the study. Overthecounter and prescription topical, inhaled, intranasal or injectable (for occasional use) corticosteroids are allowed.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Elagolix</keyword>
	<keyword>Elagolix plus Norethindrone Acetate</keyword>
	<keyword>Uterine Fibroids</keyword>
	<keyword>Elagolix Sodium</keyword>
	<keyword>Heavy Menstrual Bleeding</keyword>
</DOC>